IMCERA'S PITMAN-MOORE UNIT AND CAMBRIDGE BIOTECH ANNOUNCE A DEFINITIVE MASTER AGREEMENT IN ANIMAL HEALTH FIELD
IMCERA'S PITMAN-MOORE UNIT AND CAMBRIDGE BIOTECH ANNOUNCE
A DEFINITIVE MASTER AGREEMENT IN ANIMAL HEALTH FIELD
NORTHBROOK, Ill., Nov. 7 /PRNewswire/ -- IMCERA Group Inc. (NYSE: IMA) announced today that its Pitman-Moore animal health care unit of Lake Forest, Ill., and Cambridge Biotech Corporation (NASDAQ: CBCX) of Worcester Mass. have agreed to collaborate on the development of vaccines and diagnostic products for animal health applications.
A vaccine for the prevention of Lyme Disease in dogs is currently under development and it is expected that the vaccine will be the first product to be developed by this alliance, according to Boyd D. Wainscott, president and chief executive officer of Pitman-Moore.
"Domestic and wild animals as well as humans can be infected with Lyme Disease, which has been identified as a growing health concern with expanding geographic implications," Wainscott said. "No human vaccine is yet available, and currently available animal vaccines have produced varied results."
Under terms of the agreement, Pitman-Moore has acquired the rights to Cambridge's existing Lyme Disease program, as well as the right to use Cambridge's patented adjuvant technology in the development of various animal vaccines.
Cambridge's vaccine adjuvant has demonstrated characteristics which may offer significant advantages over other adjuvants currently in use, and is used in Pitman-Moore's GenetiVac(TM) FeLV feline leukemia vaccine, which was developed by Cambridge. The adjuvant is in preclinical studies for use in a malaria vaccine at Walter Reed Army Institute of Research, and is being evaluated at Memorial Sloan- Kettering for use as an immunotherapeutic for melanoma and colorectal cancers.
Dr. Patrick J. Leonard, president and chief executive officer of Cambridge Biotech, said, "Vaccines produced from recombinant DNA technology provide important advantages. They have the potential to be safer to use and less costly to produce. The combination of Cambridge Biotech's proven abilities in the development of recombinant DNA vaccines with Pitman-Moore's worldwide marketing and production network will serve both companies well."
Cambridge Biotech is a leader in the development of vaccines, adjuvants and monoclonal antibodies as the basis for vaccines, therapeutic and diagnostic products for humans and animals. The company also utilizes recombinant technology in the development and production of antigens, and is a major producer of viral diagnostic screening and confirmatory products.
Pitman-Moore, Inc., with net sales and operating earnings of $623 million and $74 million, respectively in fiscal 1991, is one of the world's leading animal health and nutrition companies. It markets a broad line of pharmaceuticals, biologicals, growth promotants, diagnostics, surgical and nutritional feed ingredients for livestock, poultry and companion animals.
IMCERA, a Fortune 500 company with net sales of more than $1.6 billion in fiscal 1991, has two other international, technology-based businesses -- Mallinckrodt Medical and Mallinckrodt Specialty Chemicals, both of St. Louis.
/CONTACT: Peter P. Hartman, vice president-finance and chief financial officer of Cambridge Biotech, 508-797-5777; or William Masterson of IMCERA, 708-205-2136; or F. A. Stresen-Reuter of Pitman- Moore, 708-949-3446; or Mark Cohen of Cameron Associates, 212-683-4545, for Cambridge Biotech/
(CBCX IMA) CO: Cambridge Biotech Corporation; IMCERA Group Inc. ST: Massachusetts, Illinois IN: MTC SU: SH-TS -- NY010 -- 2082 11/07/91 09:35 EST